ADAM17 and neoplasm: Additionally, the ADAM17 inhibitor ZLDI-I, by preventing 5-FU-mediated upregulation of Notch1-4, improved the anti-tumor activity of 5-FU and reversed EMT, acting in a synergic or additive way in different concentrations [536].